Skip to content
2000
Volume 28, Issue 15
  • ISSN: 1386-2073
  • E-ISSN: 1875-5402

Abstract

Aim

This study aimed to study the inhibitory effect of niraparib alone or in combination with GD2 specific antibody on Bladder Cancer (BCa).

Methods

The migration ability of BCa cells was assessed through a scratch assay. CCK-8 assay was performed to evaluate the viability of BCa cells, and Transwell invasion assays were utilized to examine invasive capacity. The expression levels of E-cadherin and vimentin in BCa cells were measured using QRT-PCR.

Results

Western blot showed the EMT level to be the lowest in the niraparib+GD2 group. The transwell invasion assay suggested that the invasion ability of BCa cells was weakened in the niraparib+GD2 group. CCK8 assay indicated that the proliferation ability of BCa cells was decreased. Scratch test suggested that the migration ability of BCa cells was weakened. PCR result showed that the niraparib + GD2 group had the most significant inhibitory effect on mRNA expression of EMT markers.

Conclusion

Niraparib combined with a GD2-specific antibody exerted a more prominent inhibitory effect on BCa.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cchts/10.2174/0113862073343602240909115320
2024-10-01
2025-12-31

  • From This Site

    /content/journals/cchts/10.2174/0113862073343602240909115320
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SaginalaK. BarsoukA. AluruJ.S. RawlaP. PadalaS.A. BarsoukA. Epidemiology of Bladder Cancer.Med. Sci. (Basel)2020811510.3390/medsci8010015 32183076
     [Google Scholar]
  2. BurgerM. CattoJ.W.F. DalbagniG. GrossmanH.B. HerrH. KarakiewiczP. KassoufW. KiemeneyL.A. La VecchiaC. ShariatS. LotanY. Epidemiology and risk factors of urothelial bladder cancer.Eur. Urol.201363223424110.1016/j.eururo.2012.07.033 22877502
     [Google Scholar]
  3. AntoniS. FerlayJ. SoerjomataramI. ZnaorA. JemalA. BrayF. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.Eur. Urol.20177119610810.1016/j.eururo.2016.06.010 27370177
     [Google Scholar]
  4. PloegM. AbenK.K.H. KiemeneyL.A. The present and future burden of urinary bladder cancer in the world.World J. Urol.200927328929310.1007/s00345‑009‑0383‑3 19219610
     [Google Scholar]
  5. JubberI. OngS. BukavinaL. BlackP.C. CompératE. KamatA.M. KiemeneyL. LawrentschukN. LernerS.P. MeeksJ.J. MochH. NecchiA. PanebiancoV. SridharS.S. ZnaorA. CattoJ.W.F. CumberbatchM.G. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors.Eur. Urol.202384217619010.1016/j.eururo.2023.03.029 37198015
     [Google Scholar]
  6. DashA. PettusJ.A.IV HerrH.W. BochnerB.H. DalbagniG. DonatS.M. RussoP. BoyleM.G. MilowskyM.I. BajorinD.F. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder.Cancer200811392471247710.1002/cncr.23848 18823036
     [Google Scholar]
  7. ZargarH. EspirituP.N. FaireyA.S. MertensL.S. DinneyC.P. MirM.C. KrabbeL.M. CooksonM.S. JacobsenN.E. GandhiN.M. GriffinJ. MontgomeryJ.S. VasdevN. YuE.Y. YoussefD. XylinasE. CampainN.J. KassoufW. Dall’EraM.A. SeahJ.A. ErcoleC.E. HorenblasS. SridharS.S. McGrathJ.S. AningJ. ShariatS.F. WrightJ.L. ThorpeA.C. MorganT.M. HolzbeierleinJ.M. BivalacquaT.J. NorthS. BarocasD.A. LotanY. GarciaJ.A. StephensonA.J. ShahJ.B. van RhijnB.W. DaneshmandS. SpiessP.E. BlackP.C. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.Eur. Urol.201567224124910.1016/j.eururo.2014.09.007 25257030
     [Google Scholar]
  8. ZlottaA.R. BallasL.K. NiemierkoA. LajkoszK. KukC. MirandaG. DrummM. MariA. ThioE. FleshnerN.E. KulkarniG.S. JewettM.A.S. BristowR.G. CattonC. BerlinA. SridharS.S. SchuckmanA. FeldmanA.S. WszolekM. DahlD.M. LeeR.J. SaylorP.J. MichaelsonM.D. MiyamotoD.T. ZietmanA. ShipleyW. ChungP. DaneshmandS. EfstathiouJ.A. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: A multi-institutional propensity score matched and weighted analysis.Lancet Oncol.202324666968110.1016/S1470‑2045(23)00170‑5 37187202
     [Google Scholar]
  9. LiN. ZhuJ. YinR. WangJ. PanL. KongB. ZhengH. LiuJ. WuX. WangL. HuangY. WangK. ZouD. ZhaoH. WangC. LuW. LinA. LouG. LiG. QuP. YangH. ZhangY. CaiH. PanY. HaoM. LiuZ. CuiH. YangY. YaoS. ZhenX. HangW. HouJ. WangJ. WuL. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer.JAMA Oncol.2023991230123710.1001/jamaoncol.2023.2283 37440217
     [Google Scholar]
  10. KnightW. MargaryanT. SanaiN. TovmasyanA. A validated LC-MS/MS method for determination of neuro-pharmacokinetic behavior of niraparib in brain tumor patients.J. Pharm. Biomed. Anal.202424511615010.1016/j.jpba.2024.116150 38657366
     [Google Scholar]
  11. AiX. PanY. ShiJ. YangN. LiuC. ZhouJ. ZhangX. DongX. HeJ. LiX. ChenG. LiX. ZhangH. LiaoW. ZhangY. MaZ. JiangL. CuiJ. HuC. WangW. HuangC. ZhaoJ. DingC. HuX. WangK. GaoB. SongY. LiuX. XiongJ. LiuA. LiJ. LiuZ. LiY. WangM. ZhangB. ZhangD. LuS. Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.J. Thorac. Oncol.20211681403141410.1016/j.jtho.2021.04.001 33915252
     [Google Scholar]
  12. TurnerN.C. BalmañaJ. PoncetC. GouliotiT. TryfonidisK. HonkoopA.H. ZoppoliG. RazisE. JohannssonO.T. ColleoniM. TuttA.N. AudehW. IgnatiadisM. MailliezA. TrédanO. MusolinoA. VuylstekeP. Juan-FitaM.J. MacphersonI.R.J. KaufmanB. MansoL. GoldsteinL.J. EllardS.L. LángI. JenK.Y. AdamV. LitièreS. ErbanJ. CameronD.A. Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: The EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study.Clin. Cancer Res.202127205482549110.1158/1078‑0432.CCR‑21‑0310 34301749
     [Google Scholar]
  13. HakomoriS. Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility.FEBS Lett.201058491901190610.1016/j.febslet.2009.10.065 19874824
     [Google Scholar]
  14. PrinettiA. LobertoN. ChigornoV. SonninoS. Glycosphingolipid behaviour in complex membranes.Biochim. Biophys. Acta Biomembr.20091788118419310.1016/j.bbamem.2008.09.001 18835549
     [Google Scholar]
  15. MiljanE.A. BremerE.G. Regulation of growth factor receptors by gangliosides.Sci. STKE20022002160re1510.1126/stke.2002.160.re15 12454318
     [Google Scholar]
  16. LedeenR. WuG. Gangliosides of the Nervous System.Methods Mol. Biol.20181804195510.1007/978‑1‑4939‑8552‑4_2 29926403
     [Google Scholar]
  17. YamamotoY. HigashimotoK. OhkawaY. SoejimaH. KanekoK. OhmiY. FurukawaK. FurukawaK. Possible regulation of ganglioside GD3 synthase gene expression with DNA methylation in human glioma cells.Glycoconj. J.202340332333210.1007/s10719‑023‑10108‑9 36897478
     [Google Scholar]
  18. NishioM. FurukawaK. Incorporation, remodeling and re-expression of exogenous gangliosides in human cancer cell lines in vitro and in vivo.Nagoya J. Med. Sci.2004671-23544 15279066
     [Google Scholar]
  19. Groux-DegrooteS. GuérardelY. JulienS. DelannoyP. Gangliosides in breast cancer: New perspectives.Biochemistry (Mosc.)201580780881910.1134/S0006297915070020 26541996
     [Google Scholar]
  20. BattulaV.L. ShiY. EvansK.W. WangR.Y. SpaethE.L. JacamoR.O. GuerraR. SahinA.A. MariniF.C. HortobagyiG. ManiS.A. AndreeffM. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis.J. Clin. Invest.201212262066207810.1172/JCI59735 22585577
     [Google Scholar]
  21. WenyaoC. ShuaiM. YifengF. XinzhiL. XiangyongQ. Combined use of niraparib enhanced the inhibitory effect of Anti-GD2 antibody on osteosarcoma cells.Discov. Oncol.202415130410.1007/s12672‑024‑01166‑y 39048747
     [Google Scholar]
  22. HakomoriS. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism.Cancer Res.1996562353095318 8968075
     [Google Scholar]
  23. CheeverM.A. AllisonJ.P. FerrisA.S. FinnO.J. HastingsB.M. HechtT.T. MellmanI. PrindivilleS.A. VinerJ.L. WeinerL.M. MatrisianL.M. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.Clin. Cancer Res.200915175323533710.1158/1078‑0432.CCR‑09‑0737 19723653
     [Google Scholar]
  24. YuR.K. TsaiY.T. ArigaT. YanagisawaM. Structures, biosynthesis, and functions of gangliosides--An overview.J. Oleo Sci.2011601053754410.5650/jos.60.537 21937853
     [Google Scholar]
  25. BirkléS. ZengG. GaoL. YuR.K. AubryJ. Role of tumor-associated gangliosides in cancer progression.Biochimie2003853-445546310.1016/S0300‑9084(03)00006‑3 12770784
     [Google Scholar]
  26. LedeenR. WuG. New findings on nuclear gangliosides: Overview on metabolism and function.J. Neurochem.2011116571472010.1111/j.1471‑4159.2010.07115.x 21214576
     [Google Scholar]
  27. LeT.V.T. SuhJ.H. KimN. ParkH.J. In silico identification of poly(ADP-ribose)polymerase-1 inhibitors and their chemosensitizing effects against cisplatin-resistant human gastric cancer cells.Bioorg. Med. Chem. Lett.20132392642264610.1016/j.bmcl.2013.02.094 23522835
     [Google Scholar]
  28. LiuJ.F. BradyM.F. MatulonisU.A. MillerA. KohnE.C. SwisherE.M. CellaD. TewW.P. ClovenN.G. MullerC.Y. BenderD.P. MooreR.G. MichelinD.P. WaggonerS.E. GellerM.A. FujiwaraK. D’AndreS.D. CarneyM. Alvarez SecordA. MoxleyK.M. BookmanM.A. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label.Phase III Trial. J. Clin. Oncol.202240192138214710.1200/JCO.21.02011 35290101
     [Google Scholar]
  29. JianW. XuH.G. ChenJ. XuZ.X. LevittJ.M. StanleyJ.A. YangE.S. LernerS.P. SonpavdeG. Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage.Anticancer Drugs201425887888610.1097/CAD.0000000000000114 24714082
     [Google Scholar]
  30. CriscuoloD. MorraF. GiannellaR. ViscontiR. CerratoA. CelettiA. New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment.J. Exp. Clin. Cancer Res.20193819110.1186/s13046‑019‑1089‑z 30791940
     [Google Scholar]
  31. TentoriL. LeonettiC. ScarsellaM. MuziA. VergatiM. ForiniO. LacalP.M. RuffiniF. GoldB. LiW. ZhangJ. GrazianiG. Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.Eur. J. Cancer200541182948295710.1016/j.ejca.2005.08.027 16288862
     [Google Scholar]
  32. LimJ. TanD.S.P. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors.Cancers (Basel)20179810910.3390/cancers9080109 28829366
     [Google Scholar]
  33. PlimackE.R. DunbrackR.L. BrennanT.A. AndrakeM.D. ZhouY. SerebriiskiiI.G. SlifkerM. AlpaughK. DulaimiE. PalmaN. Hoffman-CensitsJ. BilusicM. WongY.N. KutikovA. ViterboR. GreenbergR.E. ChenD.Y.T. LallasC.D. TrabulsiE.J. YelenskyR. McConkeyD.J. MillerV.A. GolemisE.A. RossE.A. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.Eur. Urol.201568695996710.1016/j.eururo.2015.07.009 26238431
     [Google Scholar]
/content/journals/cchts/10.2174/0113862073343602240909115320
Loading
Niraparib Enhances and Synergizes with Ganglioside GD2 to Potentiate its Inhibitory Effect on Bladder Cancer Cells
Comb Chem High Throughput Screen 28, 2697 (2025); https://doi.org/10.2174/0113862073343602240909115320
/content/journals/cchts/10.2174/0113862073343602240909115320
/content/journals/cchts/10.2174/0113862073343602240909115320
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): bladder cancer; EMT; GD2; inhibitory effect; Niraparib; PARP

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test